ArticleeLife2016
Diagnostic potential of tumor DNA from ovarian cyst fluid.
Article in eLife, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Different Doses of Nalbuphine Combined with Dexmedetomidine in Laparoscopic Oophorocystectomy.Medical science monitor : international medical journal of experimental and clinical research · 2021Trial
- Ovarian Cyst Fluid as a Resource for Diagnostic and Prognostic Biomarker Discovery in Ovarian Lesions.Cancers · 2026Review
- Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.International journal of cancer · 2026Article
- Optimization of Pre-Analytical Handling to Maintain DNA Integrity in Diagnostic Papanicolaou Tests.The Journal of molecular diagnostics : JMD · 2025Article
- MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.Scientific reports · 2025Article
- Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.International journal of cancer · 2022Article
- Article
- Detection of cryptogenic malignancies from metagenomic whole genome sequencing of body fluids.Genome medicine · 2021Article
- Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.Proteomes · 2021Review
- Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Technical and Methodological Aspects of Cell-Free Nucleic Acids Analyzes.International journal of molecular sciences · 2020Review
- The Origin and Pathogenesis of Endometriosis.Annual review of pathology · 2020Review
- Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma.Journal of extracellular vesicles · 2019Article
- Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.Science translational medicine · 2018Article
- Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.eLife · 2018Article
- Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.Virchows Archiv : an international journal of pathology · 2017Article
- Article
- Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- The potential of liquid biopsies for the early detection of cancer.NPJ precision oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
We determined whether the mutations found in ovarian cancers could be identified in the patients' ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83%) borderline tumors, 10 of 13 (77%) type I cancers, and 18 of 18 (100%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non-neoplastic cysts. Though large, prospective studies are needed to demonstrate the safety and clinical utility of this approach, our results suggest that the genetic evaluation of cyst fluids might be able to inform the management of the large number of women with these lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.